Latest Health News

InhaleRx Limited has completed the final tranche of its share placement, raising $600,000 to support its clinical-stage drug development programs targeting pain and mental health.

Eastern Metals Limited will have its trading suspension lifted on 9 January 2026, marking its return to the ASX after meeting key listing requirements.

Alcidion has been named the preferred supplier for University Hospitals Sussex's new Electronic Patient Record system, with a contract expected to exceed A$35 million over seven years. This deal builds on an existing partnership and marks a significant expansion for Alcidion in the UK healthcare IT market.

Hydrix Limited’s subsidiary has landed a significant A$2.5 million contract to develop SynCardia’s next-generation fully implantable Total Artificial Heart, marking a major step in advanced cardiovascular technology.

UC San Diego Health has begun clinical use of 4DMedical’s CT – VQ™, marking the fourth leading US academic medical centre to adopt this innovative lung imaging technology since FDA clearance. This milestone underscores 4DMedical’s rapid commercial traction and growing influence in respiratory diagnostics.

Island Pharmaceuticals has been granted a key US patent for Galidesivir, extending intellectual property protection through 2031 for treating filoviridae viruses including Marburg and Ebola. This milestone aligns with the company’s clinical development strategy and recent FDA regulatory progress.

Kingsgate Consolidated has dramatically reduced its borrowings by 68% through a new US$25 million standby loan facility, marking a significant step in its balance sheet de-gearing strategy.

Greatland Resources has reported a robust December quarter with gold and copper production rising alongside a significant cash increase, all while maintaining a debt-free balance sheet.

Nexsen Limited has initiated FDA engagement for its rapid Group B Streptococcus diagnostic sensor, aiming for expedited US market entry, while bolstering its leadership team and scientific credentials.

Island Pharmaceuticals reports ongoing FDA review of its antiviral Galidesivir, with no adverse feedback received as the regulator takes extra time to finalise guidance.

Biome Australia Limited has reported a record-breaking quarter and half-year sales performance, driven by strong demand for its clinically-backed probiotic products. Revenue surged over 40% compared to the previous year, defying typical seasonal slowdowns.

Simble Solutions has acquired exclusive rights to a cutting-edge 3D zinc oxide nanosensor technology and completed a $2.5 million placement, positioning itself to expand its IoT platform into new safety and environmental monitoring markets.